ONCOLYTICS BIOTECH INC. Additional details on the panel presentation can be found below.
Date:
Time:
Panel Title: Viral Approaches in Oncology
A live webcast of the panel presentation will be available to registered attendees of the conference through the conference website. Company management will also be participating in virtual one-on-one investor meetings at the conference. To schedule a meeting, contact your
About
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in Phase 2 studies in breast and pancreatic cancers. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype - turning cold tumors hot - through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid and hematological malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA.
Contact:
Email: jpatton@oncolytics.ca
Tel: +1-917-679-9282
Email: tim@lifesciadvisors.com
(C) 2024 Electronic News Publishing, source
